Aim: To study the role of disturbed autonomic regulation of the cardiovascular system in formation of the phenomenon of geliogeomagnetic sensitivity of patients with left ventricular ischemic dysfunction.
Material And Methods: 24-h synchronous monitoring of ECG and electromagnetic situation was made in 11 patients (mean age 49.4 +/- 0.9 years) who had survived macrofocal myocardial infarction (MI) at least 6 months before and in 15 healthy volunteers.
Results: Heart rhythm dispersion, correlation between variations of magnetic field vector component amplitudes and standard deviation of ECG R-R intervals duration in MI survivors were significantly less than in healthy subjects. High conjugacy of heart rhythm dispersion and mean value of R-R intervals (functions synchronization index) was characteristic only for the control group. A 3-week therapy with atenolol provided normalization of the disturbed correlations in 4 patients.
Conclusion: Pathogenic geliogeotropic reactions in MI survivors develop because of intra- and inter-systemic desynchronisation of the functions mechanism of which is mediated by sympathicoadrenal activation and is correctable by beta 1-adrenoblocker atenolol.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.
Background: Effective early intervention of mild cognitive impairment (MCI) is the key for preventing dementia. However, there is currently no drug for MCI. As a multi-targeted neuroprotective agent, butylphthalide has been demonstrated to repair cognition in patients with vascular cognitive impairment, and has the potential to treat MCI due to Alzheimer's disease (AD).
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is characterized by progressive atrophy of the cerebral cortex and hippocampus, with concomitant increase in ventricular volume. Lomecel-B is a novel cell-based therapeutic approach to AD that targets neuroinflammation, microvascular dysfunction, and has the potential to stimulate endogenous tissue regeneration. We conducted MRI analysis of brain morphology in the CLEAR-MIND study, a 49-patient proof-of-concept study that tested 3 different dosing regimens of Lomecel-B vs placebo in patients with mild AD dementia.
View Article and Find Full Text PDFBackground: Lomecel-B is a novel cell-based therapy with potential to demonstrate clinical benefit on Alzheimer's disease (AD) and its progression. Here we present the results of a phase 2a proof-of-concept trial (n = 49) to further define the potential of Lomecel-B in patients with mild AD dementia.
Methods: This double-blind, randomized, placebo-controlled 45-week trial (ClinicalTrials.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Department of Psychology & Language Sciences, University College London, London, United Kingdom.
Background: Dysphagia is an important feature of neurodegenerative diseases and potentially life-threatening in primary progressive aphasia (PPA), but remains poorly characterised in these syndromes. We hypothesised that dysphagia would be more prevalent in nonfluent/agrammatic variant (nfv)PPA than other PPA syndromes, predicted by accompanying motor features and associated with atrophy affecting regions implicated in swallowing control.
Methods: In a retrospective case-control study at our tertiary referral centre, we recruited 56 patients with PPA (21 nfvPPA, 22 semantic variant (sv)PPA, 13 logopenic variant (lv)PPA).
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Medical University of South Carolina, Charleston, SC, USA.
Background: Repetitive transcranial magnetic stimulation enhances cognition in people with mild cognitive impairment (MCI). Whereas conventional treatment requires daily sessions for 4-6 weeks, accelerated intermittent theta burst stimulation (iTBS) shortens the treatment course to just 3 days, substantially improving feasibility of use in people with MCI. We conducted a Phase I safety and feasibility trial of iTBS in MCI, finding preliminary evidence of cognitive improvement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!